Cronos Group Announces 2026 Annual Shareholders Meeting Details
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 29 2026
0mins
Source: Newsfilter
- Meeting Schedule: Cronos Group will hold its 2026 Annual Meeting of Shareholders on June 18, 2026, at 11:00 a.m. ET in a virtual format, ensuring equal participation for all registered shareholders and proxyholders.
- Participation Details: The meeting will be conducted via live audio webcast, allowing shareholders to ask questions and vote online, which enhances shareholder engagement and interaction, thereby improving corporate governance transparency.
- Replay Availability: A replay of the meeting will be accessible approximately 24 hours after its conclusion in the investor relations section of the company's website, ensuring that shareholders who could not attend live can still access the meeting content.
- Company Overview: Cronos is an innovative global cannabis company focused on scaling leading consumer goods products through R&D and innovation, aiming to build an iconic brand portfolio to elevate the consumer experience.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRON?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRON
Wall Street analysts forecast CRON stock price to fall
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 2.750
Low
2.30
Averages
2.72
High
3.14
Current: 2.750
Low
2.30
Averages
2.72
High
3.14
About CRON
Cronos Group Inc. is a global cannabinoid company engaged in building disruptive intellectual property by advancing cannabis research, technology and product development. The Company's diverse international brand portfolio includes Spinach, PEACE NATURALS and Lord Jones. Spinach is a mainstream adult-use cannabis brand with a portfolio that includes cannabinoid products in a wide range of formats, including dried flower, pre-rolls, vaporizers, edibles and tinctures. Lord Jones is a premium adult-use cannabis brand. The Lord Jones brand portfolio includes cannabis products in the pre-roll, vaporizer and edible categories. Lord Jones Ice Water Hash Fusions pre-rolls feature flower and terpene-rich ice water hash and are fitted with a branded ceramic tip. PEACE NATURALS is a global medical brand engaged in producing cannabis products. The Company distributes products under the PEACE NATURALS brand for the Canadian market and the Israeli, German, and United Kingdom medical markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trulieve Becomes First U.S. Cannabis Company Listed on NYSE
- Historic Listing: Trulieve successfully listed on the NYSE on June 10, becoming the first U.S. cannabis company on a major exchange, marking a significant milestone for the U.S. cannabis industry and likely attracting increased investor interest.
- Financial Performance: In its first quarter, Trulieve reported $100 million in adjusted EBITDA, while Tilray expects EBITDA between $62 million and $72 million for the year, highlighting Trulieve's superior profitability.
- Market Competition: Trulieve and Tilray now compete directly on major exchanges; although Tilray has a broader international presence, Trulieve's vertically integrated model provides better resilience against price fluctuations in the U.S. market.
- Tax Relief: With the U.S. rescheduling medical marijuana to Schedule III, Trulieve stands to benefit from reduced 280E tax burdens, significantly improving its financial outlook and reinforcing its market position.
See More
Trulieve Lists on NYSE, Competes with Tilray
- Listing Achievement: Trulieve began trading on the NYSE on June 10, becoming the first U.S. cannabis company to list on a major exchange, marking a significant milestone for the U.S. cannabis industry and potentially attracting more investor interest.
- Financial Performance Comparison: Trulieve reported $100 million in adjusted EBITDA for Q1, while Tilray expects EBITDA between $62 million and $72 million this year, highlighting Trulieve's clear advantage in profitability.
- Market Competition Landscape: With 240 dispensaries, Trulieve's operational model allows it to capture the entire retail markup, whereas Tilray, primarily a wholesale manufacturer, faces greater pricing pressure, resulting in significantly lower profit margins compared to Trulieve.
- Tax Policy Impact: The U.S. reclassification of medical marijuana to Schedule III alleviates Trulieve's 280E tax burden, which is expected to yield substantial financial benefits, further solidifying its leadership position in the market.
See More
Cronos' Spinach® Becomes Top-Selling Vape Brand in Canada
- Market Share Leadership: Cronos Group's Spinach® vape captured 10.4% of the Canadian vape market in April 2026, maintaining this leading position since January 2026, demonstrating strong consumer appeal and loyalty.
- Innovation-Driven Products: Spinach® vapes utilize high-purity extracts and advanced hardware to deliver high-quality, flavorful, and consistent experiences for adult consumers, further solidifying its competitive edge in the rapidly growing vape market.
- New Product Launches: The brand plans to introduce several new SKUs this summer, including three new flavors for the Spinach PUFFERZ™ all-in-one vape and its first limited-time offer Orange Vanilla Twist vape, which is expected to drive sales growth and attract new customers.
- Global Expansion Strategy: CEO Mike Gorenstein emphasized that Spinach®'s success in Canada validates the effectiveness of its product innovation engine and builds confidence for future expansion of cannabinoid products globally.
See More
DEA Hearing on Marijuana Rescheduling Sparks Market Optimism
- Hearing Date Set: The DEA is scheduled to hold a hearing on June 29 to discuss reclassifying marijuana from Schedule I to Schedule III, which could significantly impact commercial and medical uses across the country.
- Trump Administration Pushes Legislation: The Trump administration is urging Congress to amend the broad ban on hemp-derived products to ensure the legality of CBD products, which is expected to benefit farmers and further fuel market optimism for cannabis stocks.
- Positive Market Reaction: Following this news, shares of Tilray Brands (TLRY) rose nearly 4% in premarket trading, making it the top-trending ticker on Stocktwits, while peers like Canopy Growth (CGC), Aurora Cannabis (ACB), and Cronos (CRON) also saw their stock prices increase.
- Investor Sentiment Shift: On Stocktwits, retail sentiment regarding TLRY shifted from 'bullish' to 'extremely bullish', indicating high expectations for the upcoming DEA hearing, which could potentially alter the sentiment curve in the market.
See More
Andrew Left Convicted of Stock Manipulation Charges
- Stock Manipulation Conviction: A Los Angeles jury found Andrew Left guilty on 13 counts of stock manipulation between 2018 and 2023, highlighting the severity of his actions in leveraging social media influence for market manipulation, which could result in millions in fines and restitution.
- Profit Details: Prosecutors revealed that Left earned over $20 million by making bold stock calls on social media while secretly executing opposite trades, raising concerns about market fairness and increasing scrutiny on short sellers from regulators.
- Citron Research's Response: Following the conviction, Citron Research expressed dissatisfaction with the jury's ruling, arguing that the case could deter honest commentary from investors and market analysts, and pledged to continue fighting for free speech, indicating a commitment to ongoing legal battles.
- Impact of GameStop Incident: Left's bearish stance on GameStop in 2021 sparked significant retail trading activity; despite the conviction potentially tarnishing his reputation, he plans to short GameStop again in 2024, demonstrating his ongoing engagement with market dynamics.
See More
Andrew Left Found Guilty of Stock Manipulation, Faces Decades in Prison
- Verdict Outcome: Andrew Left was found guilty in a Los Angeles trial and faces over 20 years in prison for using social media to manipulate stocks, which threatens to tighten short-selling strategies in the market.
- Economic Impact: Prosecutors indicated that Left earned over $20 million from manipulative trades between 2018 and 2023, and this verdict may lead other short sellers to exercise greater caution, impacting trading behaviors across the industry.
- Industry Reaction: The case has drawn significant attention from short sellers, many of whom fear that it will result in stricter regulations, dampening confidence in short-selling practices and potentially affecting market liquidity.
- Legal Consequences: Left's defense attorney requested a mistrial based on the jury filling out an outdated verdict form, which could influence the final outcome of the case and prolong legal proceedings.
See More
Trulieve Becomes First U.S. Cannabis Company Listed on NYSE
- Historic Listing: Trulieve successfully listed on the NYSE on June 10, becoming the first U.S. cannabis company on a major exchange, marking a significant milestone for the U.S. cannabis industry and likely attracting increased investor interest.
- Financial Performance: In its first quarter, Trulieve reported $100 million in adjusted EBITDA, while Tilray expects EBITDA between $62 million and $72 million for the year, highlighting Trulieve's superior profitability.
- Market Competition: Trulieve and Tilray now compete directly on major exchanges; although Tilray has a broader international presence, Trulieve's vertically integrated model provides better resilience against price fluctuations in the U.S. market.
- Tax Relief: With the U.S. rescheduling medical marijuana to Schedule III, Trulieve stands to benefit from reduced 280E tax burdens, significantly improving its financial outlook and reinforcing its market position.
See More
Trulieve Lists on NYSE, Competes with Tilray
- Listing Achievement: Trulieve began trading on the NYSE on June 10, becoming the first U.S. cannabis company to list on a major exchange, marking a significant milestone for the U.S. cannabis industry and potentially attracting more investor interest.
- Financial Performance Comparison: Trulieve reported $100 million in adjusted EBITDA for Q1, while Tilray expects EBITDA between $62 million and $72 million this year, highlighting Trulieve's clear advantage in profitability.
- Market Competition Landscape: With 240 dispensaries, Trulieve's operational model allows it to capture the entire retail markup, whereas Tilray, primarily a wholesale manufacturer, faces greater pricing pressure, resulting in significantly lower profit margins compared to Trulieve.
- Tax Policy Impact: The U.S. reclassification of medical marijuana to Schedule III alleviates Trulieve's 280E tax burden, which is expected to yield substantial financial benefits, further solidifying its leadership position in the market.
See More
Cronos' Spinach® Becomes Top-Selling Vape Brand in Canada
- Market Share Leadership: Cronos Group's Spinach® vape captured 10.4% of the Canadian vape market in April 2026, maintaining this leading position since January 2026, demonstrating strong consumer appeal and loyalty.
- Innovation-Driven Products: Spinach® vapes utilize high-purity extracts and advanced hardware to deliver high-quality, flavorful, and consistent experiences for adult consumers, further solidifying its competitive edge in the rapidly growing vape market.
- New Product Launches: The brand plans to introduce several new SKUs this summer, including three new flavors for the Spinach PUFFERZ™ all-in-one vape and its first limited-time offer Orange Vanilla Twist vape, which is expected to drive sales growth and attract new customers.
- Global Expansion Strategy: CEO Mike Gorenstein emphasized that Spinach®'s success in Canada validates the effectiveness of its product innovation engine and builds confidence for future expansion of cannabinoid products globally.
See More
DEA Hearing on Marijuana Rescheduling Sparks Market Optimism
- Hearing Date Set: The DEA is scheduled to hold a hearing on June 29 to discuss reclassifying marijuana from Schedule I to Schedule III, which could significantly impact commercial and medical uses across the country.
- Trump Administration Pushes Legislation: The Trump administration is urging Congress to amend the broad ban on hemp-derived products to ensure the legality of CBD products, which is expected to benefit farmers and further fuel market optimism for cannabis stocks.
- Positive Market Reaction: Following this news, shares of Tilray Brands (TLRY) rose nearly 4% in premarket trading, making it the top-trending ticker on Stocktwits, while peers like Canopy Growth (CGC), Aurora Cannabis (ACB), and Cronos (CRON) also saw their stock prices increase.
- Investor Sentiment Shift: On Stocktwits, retail sentiment regarding TLRY shifted from 'bullish' to 'extremely bullish', indicating high expectations for the upcoming DEA hearing, which could potentially alter the sentiment curve in the market.
See More
Andrew Left Convicted of Stock Manipulation Charges
- Stock Manipulation Conviction: A Los Angeles jury found Andrew Left guilty on 13 counts of stock manipulation between 2018 and 2023, highlighting the severity of his actions in leveraging social media influence for market manipulation, which could result in millions in fines and restitution.
- Profit Details: Prosecutors revealed that Left earned over $20 million by making bold stock calls on social media while secretly executing opposite trades, raising concerns about market fairness and increasing scrutiny on short sellers from regulators.
- Citron Research's Response: Following the conviction, Citron Research expressed dissatisfaction with the jury's ruling, arguing that the case could deter honest commentary from investors and market analysts, and pledged to continue fighting for free speech, indicating a commitment to ongoing legal battles.
- Impact of GameStop Incident: Left's bearish stance on GameStop in 2021 sparked significant retail trading activity; despite the conviction potentially tarnishing his reputation, he plans to short GameStop again in 2024, demonstrating his ongoing engagement with market dynamics.
See More
Andrew Left Found Guilty of Stock Manipulation, Faces Decades in Prison
- Verdict Outcome: Andrew Left was found guilty in a Los Angeles trial and faces over 20 years in prison for using social media to manipulate stocks, which threatens to tighten short-selling strategies in the market.
- Economic Impact: Prosecutors indicated that Left earned over $20 million from manipulative trades between 2018 and 2023, and this verdict may lead other short sellers to exercise greater caution, impacting trading behaviors across the industry.
- Industry Reaction: The case has drawn significant attention from short sellers, many of whom fear that it will result in stricter regulations, dampening confidence in short-selling practices and potentially affecting market liquidity.
- Legal Consequences: Left's defense attorney requested a mistrial based on the jury filling out an outdated verdict form, which could influence the final outcome of the case and prolong legal proceedings.
See More
